Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Iovance Q3 revenue rises 80% to $121.5 million as net loss narrows

Positive Impact 3 of 5 earnings Written later

Iovance reported third quarter 2026 product revenue of $121.5 million, up about 80% from $67.5 million a year earlier, and a net loss of $22.3 million, down from $91.3 million. The company said it remains on track to meet its full-year 2026 total product revenue guidance of $410 million to $420 million.

Key points

  • Q3 2026 product revenue was $121.5 million, up about 22% from roughly $99 million in Q2 2026
  • Net loss per share was $0.05 in Q3 2026 versus $0.25 in Q3 2025
  • Full-year 2026 product revenue guidance of $410 million to $420 million was reaffirmed, not changed
  • Gross margin was about 60%, compared with 56% in Q2 2026

The filing

CompanyIOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:05 AM ET
Accession number0001104659-26-123030

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.